Skip to main content
. 2021 Mar 13;22(6):2938. doi: 10.3390/ijms22062938

Figure 1.

Figure 1

Determining the optimal concentration of moxifloxacin, bedaquiline, amikacin, clofazimine, linezolid and cycloserine in hMDMs infected with BCG. hMDMs, obtained from healthy blood donors, were infected with BCG for three hours and were subsequently treated with (A) moxifloxacin (0.0625, 0.3125, 3.125 and 12.5 µg/mL; n = 6), (B) bedaquiline (0.05, 0.5, 1 and 5 µg/mL; n = 3–4), (C) amikacin (0.05, 0.5, 1 or 5 µg/mL; n = 3–4), (D) clofazimine (0.0125, 0.05, 0.1 and 1 µg/mL; n = 4–5), (E) linezolid (0.05, 0.5, 1, 5 and 10 µg/mL; n = 3–7) or (F) cycloserine (0.05, 0.5, 1, 5 and 10 µg/mL; n = 3–7). Twenty-four hours post BCG infection, 25% of the cell supernatant was removed and the cells supplemented with 25% fresh cRPMI. Five days post infection, a mycobacterial growth inhibition assay (MGIA) was employed to investigate the capacity to control the growth of BCG in response to the second-line TB antimicrobials. Treatments deemed to increase time to positivity (TTP), shown in days, indicates a bactericidal or bacteriostatic effect; such inhibition in BCG growth can also be illustrated when plotted as percentage change in TTP (% change TTP; see methods section for description). The smallest antimicrobial concentration to significantly reduce TTP by >10% was chosen. Bars denote mean ± SEM. * p < 0.05 and ** p < 0.01 (mixed effects REML and Friedman ANOVA tests with Dunnett’s/Dunn’s multiple comparisons tests).